A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

I8D-MC-AZET -

Trial Summary

Age Range
55 - 85 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
Lanabecestat (LY3314814)
Could I receive a Placebo?
Yes
Enrollment Goal
1722
Trial Dates
Jul 1, 2016 - Sep 28, 2018
How long will I be in the trial?
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.